Rallybio (RLYB) Liabilities and Shareholders Equity (2020 - 2026)

Rallybio has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $54.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 6.06% year-over-year to $54.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.4 million (down 20.88% YoY) and the FY2025 annual result came in at $62.3 million, down 8.58% from the prior year.
• Liabilities and Shareholders Equity slipped to $54.5 million in Q1 2026 per RLYB's latest filing, from $62.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $180.4 million in Q4 2022 and troughed at $51.0 million in Q2 2025.
• A 5-year average of $108.2 million and a median of $99.4 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity grew 29.57% in 2022, then slumped 44.82% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $180.4 million in 2022, then sank by 35.92% to $115.6 million in 2023, then plunged by 41.09% to $68.1 million in 2024, then decreased by 8.58% to $62.3 million in 2025, then decreased by 12.51% to $54.5 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $54.5 million, $62.3 million, and $67.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.